CRISCuris, Inc.
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral s…
Industry Peers
Biotechnology| Headline | Source | Time |
|---|---|---|
Older | ||
 Curis (CRIS) Stock Fair Value Moves Lower After Emavusertib TakeAim Model Rework The fair value price target for Curis has been reset from US$280.00 to US$42.67, which represents a very large downward adjustment in the modeled target level. Analysts link this shift to updated assumptions around emavusertib and the TakeAim chronic lymphocytic leukemia study, where price targets now reflect explicit probabilities of success, peak sales estimates and timing. As you read on, you will see how this evolving narrative around Curis might influence the way you track the stock from... | ||
 Curis Gains As Blood Cancer Drug Progresses, December Readout in Focus On Wednesday, Curis Inc. announced updated positive clinical trial results for its investigational drug emavusertib, alongside expanded trial timeline guidance. The biotechnology firm detailed key advances across its ongoing clinical programs evaluating the oral IRAK4 and FLT3 inhibitor for targeted... | ||
Curis (CRIS) Stock Sees Fair Value Lift As Analysts Back Leadership And Consumer Focus Curis is back in focus after analysts lifted their fair value estimate from US$14 to US$280, a very large reset in what they consider a reasonable long term outcome for the stock. This shift is being framed around improved leadership and a heavier emphasis on direct to consumer channels, while more cautious voices question how much of that story is already reflected in the higher figure. Read on to see how this evolving narrative could shape expectations and what to watch as new information... | ||
 Curis shares surge after updated emavusertib data strengthens clinical outlook (NASDAQ:CRIS) New lymphoma results support development programmeCuris, Inc. (NASDAQ:CRIS) shares climbed 11% on Wednesday after the biotechnology company released encouraging updated clinical data for emavusertib in patients with Primary CNS Lymphoma (PCNSL) and raised enrollment expectations for its Chronic Lymphocytic Leukemia (CLL) study. | ||